STK11IP Antibody

What is STK11IP and why is it significant in molecular research?

STK11IP (serine/threonine Kinase 11 Interacting Protein) is a protein that plays a crucial role in several cellular processes, particularly through its interaction with lysosomal components. STK11IP has gained significant attention as a substrate of mTORC1 that regulates lysosomal acidification through V-ATPase and functions as an autophagy inhibitor . Research has demonstrated that knockout of STK11IP leads to a robust increase in autophagy flux, highlighting its importance in cellular homeostasis mechanisms . Dephosphorylation of STK11IP at Ser 404 specifically represses its role as an autophagy inhibitor, creating a direct link between mTORC1 signaling and autophagy regulation . The protein is primarily localized in lysosomes, where it co-localizes with LAMP2 (a lysosomal membrane marker) and partially with Rab7 (an endosome, autophagosome, and lysosome marker) .

What types of STK11IP antibodies are currently available for research applications?

Researchers have access to a diverse range of STK11IP antibodies that vary in host species, clonality, target regions, and conjugation status:

This variety enables researchers to select antibodies specifically suited to their experimental requirements and detection methods .

How should I validate the specificity of an STK11IP antibody for my research?

Validating antibody specificity is critical for obtaining reliable experimental results. For STK11IP antibodies, a multi-step validation approach is recommended:

• Positive and negative controls: Use samples with known STK11IP expression levels, including STK11IP knockout cells as negative controls .

• Western blot analysis: Verify that the antibody detects a band of the expected size (~125 kDa for full-length STK11IP). The band should disappear or be significantly reduced in STK11IP knockout samples .

• Immunoprecipitation followed by mass spectrometry: This approach can confirm that the antibody is indeed pulling down STK11IP rather than cross-reacting with other proteins.

• Immunofluorescence with co-localization studies: STK11IP antibodies should show co-localization with lysosomal markers like LAMP2, as STK11IP is predominantly found in lysosomes . Lack of co-localization with mitochondrial markers (Tom20) or early endosome markers (EEA1) can serve as negative controls .

• Phospho-specific antibody validation: For phospho-specific antibodies like anti-STK11IP/pS404, treatment with phosphatase inhibitors or mTOR inhibitors should show appropriate changes in signal intensity .

How can I use STK11IP antibodies to investigate autophagy regulation?

STK11IP plays a critical role in autophagy regulation, making STK11IP antibodies valuable tools for studying this process:

• Monitoring STK11IP phosphorylation states: Use phospho-specific antibodies against pS404-STK11IP to track mTORC1-dependent phosphorylation in response to treatments that activate or inhibit autophagy. The phosphorylation at S404 is sensitive to rapamycin and mTOR kinase inhibitors (e.g., Torin1 and BEZ235) but not to inhibitors of S6K, p38 MAPK, JNK, or ERK .

• Co-immunoprecipitation experiments: Use STK11IP antibodies to pull down protein complexes and investigate interactions with autophagy regulators, particularly components of the mTORC1 pathway. STK11IP has been shown to interact with Raptor, mTOR, and PRAS40, but not Rictor .

• Comparative studies with STK11IP mutants: Compare wild-type STK11IP with phosphorylation site mutants (S404A and S404D) to understand how phosphorylation affects autophagy. In rescue experiments, S404A-STK11IP mutants increased LC3II levels and GFP-LC3 puncta numbers compared to wild-type and S404D mutant STK11IP .

• Autophagy flux measurements: Use STK11IP antibodies in conjunction with LC3 turnover assays or GFP-LC3-RFP probes to measure how manipulation of STK11IP affects autophagy flux in different cellular contexts .

What are the technical considerations for using phospho-specific STK11IP antibodies in mTORC1 signaling research?

Phospho-specific antibodies against STK11IP require special technical considerations:

• Phosphatase inhibitor usage: Always include phosphatase inhibitors in lysis buffers to prevent dephosphorylation of STK11IP during sample preparation. This is particularly important when studying the pS404 site, which is regulated by mTORC1 .

• Treatment conditions: For positive controls, serum stimulation following starvation can activate mTORC1 and increase STK11IP phosphorylation. Negative controls should include treatments with mTOR inhibitors like rapamycin, Torin1, or BEZ235, which have been shown to inhibit pS404-STK11IP .

• Specificity verification: Confirm the specificity of phospho-antibodies by comparing signals in wild-type cells versus cells expressing phospho-site mutants (S404A) .

• Combined analysis with other mTORC1 substrates: When studying STK11IP phosphorylation, concurrently monitor other established mTORC1 substrates (e.g., S6K, 4E-BP1) to contextualize STK11IP regulation within the broader mTORC1 signaling network.

• Subcellular fractionation: Since STK11IP is primarily localized to lysosomes, consider performing subcellular fractionation to enrich lysosomal fractions before immunoblotting with phospho-specific antibodies to increase detection sensitivity .

How can I optimize STK11IP antibody use for co-localization studies with lysosomal markers?

Optimizing co-localization studies requires careful attention to several technical aspects:

What experimental approaches can determine STK11IP's interaction with V-ATPase using antibodies?

Research has established that STK11IP regulates lysosomal acidification through interaction with V-ATPase. To investigate this interaction:

• Co-immunoprecipitation (Co-IP): Use STK11IP antibodies to immunoprecipitate native protein complexes, followed by immunoblotting for V-ATPase subunits. This approach can confirm physical interaction between STK11IP and V-ATPase components .

• Reciprocal Co-IP: Perform the reverse experiment using antibodies against V-ATPase subunits to pull down complexes, then blot for STK11IP to validate the interaction.

• Proximity ligation assay (PLA): This technique can detect protein interactions in situ with high sensitivity. Using primary antibodies against STK11IP and V-ATPase subunits followed by PLA probes can visualize interactions as fluorescent spots under microscopy.

• Subcellular fractionation with gradient centrifugation: Isolate lysosomal fractions using differential centrifugation, then probe for both STK11IP and V-ATPase subunits to determine their co-occurrence in the same subcellular compartment .

• FRET or BRET analysis: When using fluorescently tagged proteins, these energy transfer techniques can provide evidence of direct protein interactions within living cells.

How can STK11IP antibodies be utilized in metabolic disease research?

STK11IP has emerging significance in metabolic disorders, particularly in fatty liver disease models:

• Tissue immunohistochemistry: STK11IP antibodies can be used for IHC analysis of liver tissue samples from models of metabolic dysfunction. Studies show that STK11IP knockout protects mice from fasting or Methionine/Choline-Deficient Diet (MCD)-induced fatty liver .

• Phosphorylation status monitoring: Use phospho-specific antibodies to track STK11IP phosphorylation changes in response to different metabolic conditions. The pS404-STK11IP level has been shown to decrease upon endurance treadmill exercise, linking STK11IP regulation to physical activity .

• Autophagy assessment in metabolic tissues: Combine STK11IP antibody staining with autophagy markers to evaluate how STK11IP influences tissue-specific autophagy in metabolic disorders. STK11IP knockout mice exhibit higher levels of LC3II conversion in the soleus muscle under both resting and endurance exercise conditions .

• Colocalization with lipid droplet markers: This approach can help investigate STK11IP's potential role in lipophagy, a specialized form of autophagy involved in lipid metabolism.

• Therapeutic target validation: STK11IP represents a promising therapeutic target for diseases with aberrant autophagy signaling . Antibodies can be used to validate target engagement in preclinical models testing STK11IP-modulating compounds.

What are the best practices for using STK11IP antibodies in multi-color flow cytometry?

When incorporating STK11IP antibodies into multi-color flow cytometry panels:

• Antibody panel design: Consider the fluorophore brightness hierarchy when assigning fluorochromes to antibodies. For intracellular proteins like STK11IP that may have lower expression, use brighter fluorophores (PE, APC) rather than dimmer ones (FITC).

• Fixation and permeabilization optimization: Since STK11IP is an intracellular protein, proper cell permeabilization is crucial. Test different commercial permeabilization kits (e.g., BD Cytofix/Cytoperm, eBioscience Foxp3 Fix/Perm) to determine which provides optimal detection of STK11IP while maintaining surface marker integrity.

• Compensation controls: When using conjugated STK11IP antibodies in multi-color panels, prepare single-color controls for each fluorochrome to establish proper compensation matrices. Beads may be used for most surface markers, but for intracellular markers like STK11IP, use cells with known expression.

• Titration experiments: Determine the optimal concentration of STK11IP antibodies by titration to achieve maximum separation between positive and negative populations while minimizing background.

• Gating strategy development: Start with viable single cells, then use isotype or fluorescence-minus-one (FMO) controls to establish positive/negative boundaries for STK11IP staining.

What are common troubleshooting strategies for weak or non-specific STK11IP antibody signals?

When encountering difficulties with STK11IP antibody detection:

• Epitope masking issues: STK11IP's lysosomal localization may cause epitope masking. Try different fixation methods (paraformaldehyde vs. methanol) or antigen retrieval techniques (heat-induced vs. enzymatic) to improve epitope accessibility.

• Cross-reactivity assessment: Test the antibody on STK11IP knockout samples as negative controls to confirm specificity . If signal persists in knockout samples, consider alternative antibodies targeting different regions of STK11IP.

• Protein extraction optimization: Since STK11IP is membrane-associated in lysosomes, standard lysis buffers may not efficiently extract the protein . Use buffers containing stronger detergents (RIPA or buffers with increased NP-40/Triton X-100 concentrations) for more complete extraction.

• Signal amplification methods: For low abundance detection, consider using signal amplification techniques such as tyramide signal amplification (TSA) or polymer-based detection systems.

• Batch variability management: Different lots of the same antibody may show performance variations. Maintain a reference sample to validate each new antibody lot before use in critical experiments.

How can I design quantitative experiments to measure STK11IP levels or phosphorylation states?

For accurate quantification of STK11IP or its phosphorylation:

• Western blot quantification: Use housekeeping proteins (β-actin, GAPDH) or total protein staining (Ponceau S, REVERT) for normalization. For phospho-specific detection, normalize phospho-STK11IP signal to total STK11IP rather than housekeeping proteins .

• ELISA development: Consider developing sandwich ELISA assays with capture antibodies against STK11IP and detection antibodies against phospho-sites or total protein for high-throughput quantification.

• Mass spectrometry-based quantification: For absolute quantification, develop selected reaction monitoring (SRM) or parallel reaction monitoring (PRM) assays using synthetic peptide standards corresponding to regions of interest in STK11IP.

• Image-based quantification: When using immunofluorescence, establish consistent exposure settings and analysis parameters. For phosphorylation studies, calculate the ratio of phospho-STK11IP to total STK11IP on a cell-by-cell basis using image analysis software.

• Normalization strategies: Always include internal controls and biological replicates. For phosphorylation studies under mTORC1 inhibition, include known mTORC1 substrates as positive controls to contextualize STK11IP phosphorylation changes .

How might emerging antibody technologies advance STK11IP research?

Novel antibody technologies offer new opportunities for STK11IP research:

• Nanobodies and single-domain antibodies: These smaller antibody fragments may provide better access to epitopes in complex structures like lysosomes, potentially improving detection of membrane-associated proteins like STK11IP.

• Intrabodies: Genetically encoded antibody fragments that can be expressed within cells may allow real-time tracking of STK11IP localization and interactions in living cells.

• BiTE (Bispecific T-cell Engager) technology: Although primarily developed for cancer immunotherapy, the bispecific antibody design principle could be adapted to create research tools that simultaneously target STK11IP and interacting partners.

• Antibody-based proximity labeling: Techniques like APEX2 or TurboID fused to anti-STK11IP antibody fragments could identify proteins in close proximity to STK11IP in lysosomes, expanding our understanding of its interaction network.

• Mass cytometry (CyTOF) integration: Metal-conjugated STK11IP antibodies could enable high-dimensional analysis of STK11IP in relationship to dozens of other cellular markers simultaneously, providing a systems-level view of its regulation.

What are emerging areas of research where STK11IP antibodies may have significant impact?

Current research suggests several promising directions where STK11IP antibodies could make important contributions:

• Neurodegenerative disease research: Given STK11IP's role in autophagy regulation, it may be relevant to neurodegenerative diseases characterized by protein aggregation and autophagy dysfunction. STK11IP antibodies could help investigate its potential role in these conditions .

• Cancer metabolism studies: STK11IP's connection to mTORC1 signaling makes it potentially relevant to cancer metabolism and growth. Antibodies could help characterize its expression and phosphorylation state across different cancer types.

• Exercise physiology: The observation that pS404-STK11IP levels decrease after endurance exercise suggests a potential role in exercise-induced metabolic adaptations . STK11IP antibodies could help explore this connection further.

• Aging research: As autophagy is implicated in aging processes, STK11IP's role as an autophagy regulator makes it a candidate for investigation in aging studies . Age-dependent changes in STK11IP expression or phosphorylation could be monitored using appropriate antibodies.

• Drug discovery programs: STK11IP has been identified as a promising therapeutic target for diseases with aberrant autophagy signaling . Antibodies will be essential tools in screening and validating compounds that modulate STK11IP function or expression.